
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Elysium Completes FDA Pre-IND For Tech To Combat Fentanyl Overdose
Details : SOOPR (naloxone) is an opioid receptor antagonist indicated in the reversal of opioid overdoses.
Product Name : SOOPR
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2025
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Elysium Reports Human Proof-of-Concept Data for O2P Hydrocodone Prodrug for Acute Pain
Details : ETR028, first- and best-in-class, oral-overdose protected (O2P) hydrocodone prodrug being developed for the treatment of moderate-to-severe acute pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 05, 2024

Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
Details : ETR028 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acute Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 07, 2022
